{"id":30406,"date":"2020-03-28T11:36:48","date_gmt":"2020-03-28T11:36:48","guid":{"rendered":"http:\/\/biomedpharmajournal.org\/?p=30406"},"modified":"2021-07-31T08:17:53","modified_gmt":"2021-07-31T08:17:53","slug":"double-plication-of-basilic-vein-of-brachial-basilic-arteriovenous-fistula-as-effective-treatment-for-dialysis-related-steal-syndrome-dress-a-case-report","status":"publish","type":"post","link":"https:\/\/biomedpharmajournal.org\/staging\/vol13no1\/double-plication-of-basilic-vein-of-brachial-basilic-arteriovenous-fistula-as-effective-treatment-for-dialysis-related-steal-syndrome-dress-a-case-report\/","title":{"rendered":"Double Plication of Basilic Vein of Brachial-Basilic Arteriovenous Fistula as Effective Treatment for Dialysis Related Steal Syndrome (DRESS) : A  Case Report"},"content":{"rendered":"<p><strong>Introduction<\/strong><\/p>\n<p>Overall incidence of steal syndrome in AVF is 1% to 9%, but can produce devastating complication hand ischemia (1), this frequency increases depending on the type of AVF <u>(<\/u>2, 3), and were predominantly (83%) brachial based (4).<\/p>\n<p>There were several different term for hand ischemia related to vascular access such as hemodialysis access-induced distal ischaemia or HAIDI (3), distal hypoperfusion ischemic syndrome or DHIS (5), dialysis associated steal syndrome or DASS (6), arteriovenous access ischemic steal in hemodialysis or AVAIS (7), vascular access-induced steal syndrome or VASS (8), ischemic steal syndrome (ISS) associated with arteriovenous access (9).<\/p>\n<p>Steal syndrome related to dialysis in AVF occurs when perfusion from the distal portion of the AVF become insufficient caused by more blood flowing towards the fistula than to the distal portion of the AVF , blood being diverted to support the access. It is one the most dreadful complications of vascular access creation.\u00a0 Diagnosis of steal syndrome related to dialysis is primarily\u00a0 clinical based on signs and symptoms of hand ischemia include pallor, absent distal pulse, coldness, pain,\u00a0 paraesthesia over hand and finger, weakness on hand grip, tissue loss such as ulcer or gangrene of fingers (6).\u00a0 Understand about pathophysiology is very importan for making diagnosis, investigation and management. Steal syndrome clinically is not simply blood diversion but also pressure changes within intravascular of\u00a0 distal portion of AVF to produce hypoperfusion and resultant poor perfusion pressures in the distal extremity (7).<\/p>\n<p>There are several methods for treating DRESS in accordance with the different causes and conditions such as : endovascular treatment for peripheral arterial disease, plication with or without banding of venous segmen enlargement of AVF, ligation of outflow veins branches, revision using distal inflow (RUDI), proximalization of arterial inflow (PAI), distal revascularization and interval ligation (DRILL) or\u00a0 without interval ligation (6).<\/p>\n<p><strong>Case<\/strong><\/p>\n<p>A Male 57 years old, complain\u00a0 numbness and pain at rest on\u00a0 finger\u00a0 4<sup>th<\/sup> and 5<sup>th<\/sup> left hand,\u00a0 weakness on hand grip after 2 weeks left brachial-basilic AVF creation for hemodialysis access. Physical examination there was found absent distal pulse\u00a0 of radial and ulnar artery, coldness on palmar and dorsal hand. There was no history of diabetes, coronary artery diseases, and cerebrovascular diseases. Chronic kidney disease (CKD) was diagnosed with routine hemodialysis 2 times a week, and Dialysis Associated Steal Syndrome (DASS) was supected. Internal jugular temporary catheter was inserted for hemodialysis vascular access. Catheter-directed angiography was performed to investigate any causes of DASS. Preferential blood flow to\u00a0 brachio-basilic AVF access was detected with relative\u00a0 enlarge size of basilic vein\u00a0 without adequate blood flow to distal artery below the AVF (Figure 1). Visible enlargement of basilic vein size (&gt; 6 mm), and palpable strong thrill (Figure 3).\u00a0 Double plication of basilic vein near the\u00a0 anastomosis brachial-basilic AVF was performed under local anesthesia using Satinsky vascular clamp, double mattress\u00a0 and continuous suture with prolene until it reaches the desired size (double plication) (Figure 4 and Figure 5). The angiogram after plication show that arterial blood flow to distal was came back to normal (Figure 2), with significant palpable pulse of radial and ulnar artery. Immediate gradual symptom resolution after plication and\u00a0 complete resolution was achieve in 1 month postoperative.<\/p>\n<table style=\"width: 70%;\" border=\"1\" cellpadding=\"5\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" class=\"alignnone wp-image-30412 size-thumbnail\" src=\"https:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig1-150x150.jpg\" alt=\"Figure 1:Preferential blood flow to brachial-basilic AVF before plication of basilic vein\" width=\"150\" height=\"150\" srcset=\"https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig1-150x150.jpg 150w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig1-256x256.jpg 256w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig1.jpg 265w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/td>\n<td><strong>Figure 1:\u00a0<\/strong><strong>Preferential blood flow to\u00a0<\/strong><strong>brachial-basilic AVF\u00a0 before plication of basilic vein<\/strong><\/p>\n<p><a href=\"http:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig1.jpg\" target=\"_blank\">Click here to View figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<table style=\"width: 70%;\" border=\"1\" cellpadding=\"5\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" class=\"alignnone wp-image-30413 size-thumbnail\" src=\"https:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig2-150x150.jpg\" alt=\"Figure 2:Balance blood flow to brachial-basilic AVF and distal artery after plication of basilic vein\" width=\"150\" height=\"150\" srcset=\"https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig2-150x150.jpg 150w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig2.jpg 242w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/td>\n<td><strong>Figure 2: Balance blood flow to brachial-basilic AVF and distal artery after\u00a0 plication of basilic vein<\/strong><\/p>\n<p><a href=\"http:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig2.jpg\" target=\"_blank\">Click here to View figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<table style=\"width: 70%;\" border=\"1\" cellpadding=\"5\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" class=\"alignnone wp-image-30414 size-thumbnail\" src=\"https:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig3-150x150.jpg\" alt=\"Figure 3: Enlarge size of cephalic vein (&gt;6 mm) of rachial-cephalic AVF\" width=\"150\" height=\"150\" srcset=\"https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig3-150x150.jpg 150w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig3-256x256.jpg 256w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig3.jpg 271w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/td>\n<td><strong>Figure 3: Enlarge size of cephalic vein\u00a0<\/strong><strong>(&gt;6 mm) of\u00a0 rachial-cephalic\u00a0 AVF<\/strong><br \/>\n<a href=\"http:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig3.jpg\" target=\"_blank\">Click here to View figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<table style=\"width: 70%;\" border=\"1\" cellpadding=\"5\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" class=\"alignnone wp-image-30415 size-thumbnail\" src=\"https:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig4-150x150.jpg\" alt=\"Figure 4: Satinsky clamping of cephalic vein brachial-cephalic AVF\" width=\"150\" height=\"150\" srcset=\"https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig4-150x150.jpg 150w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig4-256x256.jpg 256w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig4.jpg 286w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/td>\n<td><strong>Figure 4: Satinsky clamping\u00a0<\/strong><strong style=\"font-family: inherit; font-size: inherit;\">of cephalic vein brachial-<\/strong><strong>cephalic AVF<\/strong><\/p>\n<p><a href=\"http:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig4.jpg\" target=\"_blank\">Click here to View figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<table style=\"width: 70%;\" border=\"1\" cellpadding=\"5\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" class=\"alignnone wp-image-30416 size-thumbnail\" src=\"https:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig5-150x150.jpg\" alt=\"Figure 5 :Double plication of cephalic vein of brachial-cephalic AVF\" width=\"150\" height=\"150\" srcset=\"https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig5-150x150.jpg 150w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig5-256x256.jpg 256w, https:\/\/biomedpharmajournal.org\/staging\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig5.jpg 267w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/td>\n<td><strong>Figure 5 : Double plication of cephalic vein\u00a0 of brachial-cephalic\u00a0 AVF<\/strong><\/p>\n<p><a href=\"http:\/\/biomedpharmajournal.org\/wp-content\/uploads\/2020\/01\/Vol13No1_Dou_Ket_Fig5.jpg\" target=\"_blank\">Click here to View figure<\/a><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n<p><strong>Discussion<\/strong><\/p>\n<p>The severity of hand ischemia affects its management of DRESS. In grade 1 (mild) with few symptoms cool of extremity, no treatment needed. In grade 2 (moderate) with symtoms of\u00a0 intermittent claudication\u00a0 during dialysis, intervention sometimes needed. In\u00a0 grade 3 (severe) with symptoms of\u00a0 ischemic pain at rest or\u00a0 tissue loss, intervention is mandatory (6). In our case was classified\u00a0 as grade 3 (severe), therefore intervention was mandatory.<\/p>\n<p>Others classification of haemodialysis access-induced distal ischemia was based on time onset after AVF creation, classified as \u2018acute\u2019 is less than 24 hours, \u2018subacute\u2019 is within 1 month or \u2018chronic\u2019 is over than 1 month (3). The other one\u00a0 classification is early, when less than 30 days or late when\u00a0 30 or more day presentation\u00a0 (10). In our case was subacute, with symptoms occurs in 2 weeks after autogenous brachial-basilic AVF creation. As same as others report that subacute hemodialysis access-induced distal ischemia is 4 times more in autogenous AVF than grafts. Otherwise\u00a0 chronic onset was\u00a0 91% more common in autogenous AVF and AVF creation in the cubital segment. In contrast, acute onset was\u00a0 88% correlated with non-autogenous AVF (3).<\/p>\n<p>Treatment strategy of DRESS depends on the causes, severity, and general condition (6). In our case the cause is high flow fistula access because in angiogram, the contrast preference flow\u00a0 toward fistula, without any signs of distal arterial obstructive disease. The criteria of high flow AVF is when flow as much as 1000-1500 ml\/minute (2). In\u00a0 brachial-cephalic cubital AVF with steal syndrome there was significant higher volume flows were seen into venous segment fistula compared to those without steal (11). The principal treatment of high flow AVF are increased the resistance and reduced the flow into large lumen venous fistula. There are several methods can be used such as\u00a0 plication of venous segment near the anastomosis AVF, PTFE banding, or minimally invasive limited ligation endoluminal-assisted revision (MILLER) banding (2,6). Reverse of the limb ischemia symptoms and preserving the vascular access, are the goal of DRESS management (6). Success rate of distal revascularization-interval ligation (DRIL) procedure was 83% to 100%, therefore in many center it has become the preferred method to treat steal syndrome (1). Most patients with normal\/high-flow AVFs with or without distal peripheral arterial disease, DRILL is effective as treatment (2)<strong>, <\/strong>especially in patients who can tolerate a major operation (12). However, this operation was complex procedure.<\/p>\n<p>The reports regarding plication of an AVF to treat ischemic steal syndrome was limited (1)<strong>. <\/strong>There are reports about efficacy of plication to treat Ischemic steal syndrome with pathologic high flow and revealed good durability. It was reported that assisted primary patency was 87% at 1 year and 69% at 3 years, secondary patency was 90% at 1 year and 73% at 3 years (4). Plication should be considered as an alternative treatment before performance of a DRILL procedure, and\u00a0 may be an effective treatment to treat steal syndrome (1), because \u00a0DRILL was the most frequent choice for late intervention (9). In our case we performed double plication with immediate gradual symptom resolution and\u00a0 complete resolution was achieve in 1 month postoperative. Narrowing of the\u00a0 vein lumen of AVF longitudinally, has a goal to\u00a0 reduce blood flow towards the fistula and improve circulation to the distal forearm (13).<\/p>\n<p><strong>References<\/strong><\/p>\n<ol>\n<li>Yaghoubian A and de Virgilio C. Plication as Primary Treatment of Steal Syndrome in Arteriovenous Fistulas. <em>Ann Vasc Surg,<\/em> 2009<em> ; <\/em>23 :103-7.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.avsg.2008.08.009\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Tordoir J.H.M, Dammers R, van der Sande F.M. Review : Upper Extremity Ischemia and Hemodialysis Vascular Access. <em>Eur J Vasc Endovasc Surg, <\/em>\u00a02004 ; 27:1\u20135.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.ejvs.2003.10.007\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Scheltinga M.R, van Hoek F,\u00a0 Bruijninckx C.M.A. Time of onset in haemodialysis access-induced distal ischaemia (HAIDI) is related to the access type. <em>Nephrol Dial Transplant,<\/em>\u00a0 2009 ; 24: 3198\u20133204.<br \/>\n<a href=\"https:\/\/doi.org\/10.1093\/ndt\/gfp200\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Loh T. M, Bennett M.E, Peden E. K. Plication of Arteriovenous Access for Ischemic Steal Syndrome and Pathologic High Flow, Durable and Effective. J<em>ournal of Vascular Surgery (Supplement),<\/em> 2015 : 144S.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.jvs.2015.04.275\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Leon C and Asif A. Arteriovenous Access and Hand Pain: The Distal Hypoperfusion Ischemic Syndrome. <em>Clin J Am Soc Nephrol. <\/em>2007 ; <em>\u00a0<\/em>2: 175\u2013183.<br \/>\n<a href=\"https:\/\/doi.org\/10.2215\/CJN.02230606\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Ho J. P. Prevention, Diagnosis and Management of Steal Syndrome. In : Ho J.P, Cho K. J, Ko P. J, Chu S.Y, Gopinathan A., editors. <em>Practical Guide to Surgical and Endovascular Hemodialysis Access Management<\/em>. Singapore : World Scientific Publishing Co. Pte. Ltd. 2016 : 179 \u2013 204.<br \/>\n<a href=\"https:\/\/doi.org\/10.1142\/9789814675352_0012\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Inston N, Schanzer H, Widmer M, Deane C, Wilkins J, Davidson I, Gibbs P, Zanouw J, Bourquelot P, Valenti D. Arteriovenous access ischemic steal (AVAIS) in haemodialysis: a consensus from the Charing Cross Vascular Access Masterclass 2016. <em>The Journal of Vascular Access<\/em>, 2016 ; 18 (1) : 3-12. https:\/\/doi.org\/10.5301\/jva.5000621<br \/>\n<a href=\"https:\/\/doi.org\/10.5301\/jva.5000621\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Berman S.S. Understanding Steal Syndrome: Causes and Prevention Strategies to prevent the development of significant VASS. <em>ENDOVASCULAR TODAY<\/em>, 2009 : 70-72<\/li>\n<li>Gupta N, You T.H, Konig IV G, Dillayou E, Leers S. A, Chaer R.A, Cho J.S, Makaroun M.S. Treatment strategies of arterial steal after arteriovenous access.<em> J Vasc Surg<\/em>,, 2011 ; 54 : 162-7.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.jvs.2010.10.134\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Zamani P, Kaufman J, Kinlay S. Ischemic steal syndrome following arm arteriovenous fistula for hemodialysis. <em>Vascular Medicine<\/em>, 2009 ; 14: 371\u2013376.<br \/>\n<a href=\"https:\/\/doi.org\/10.1177\/1358863X09102293\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Bavare C.S, Bismuth J, El-Sayed H.F, Huynh T.T, Peden E.K, Davies M.G, Lumsden A.B,\u00a0 Naoum J.J. Volume Flow Measurements in Arteriovenous Dialysis Access in Patients with and without Steal Syndrome. <em>International Journal of Vascular Medicine<\/em>, 2013.<br \/>\n<a href=\"https:\/\/doi.org\/10.1155\/2013\/328601\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Leake A.E, Winger D.G, Leers S.A,\u00a0 Gupta N,\u00a0 Dillavou E.D. Management and outcomes of dialysis access-associated steal syndrome.<em> J Vasc Surg<\/em>,\u00a0 2015 ; 61:754-61.<br \/>\n<a href=\"https:\/\/doi.org\/10.1016\/j.jvs.2014.10.038\" target=\"_blank\">CrossRef<\/a><\/li>\n<li>Stolic R.V, Mijailovic M.Z, Cvetcovic A.M, Stanojevic M.S, Stolic D.Z, Cvetcovic D.M. Distal ischemia induced by vascular access for hemodialysis &#8211; a case report. <em>HIPPOKRATIA<\/em>, 2012 ; 16 (4) : 375-377.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Introduction Overall incidence of steal syndrome in AVF is 1%  [&#8230;]<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[75],"tags":[],"class_list":["post-30406","post","type-post","status-publish","format-standard","hentry","category-vol13no1"],"_links":{"self":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/30406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/comments?post=30406"}],"version-history":[{"count":5,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/30406\/revisions"}],"predecessor-version":[{"id":40034,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/posts\/30406\/revisions\/40034"}],"wp:attachment":[{"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/media?parent=30406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/categories?post=30406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biomedpharmajournal.org\/staging\/wp-json\/wp\/v2\/tags?post=30406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}